Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CDC25B | P30305 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | PTPRC | P08575 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | APAF1 | O14727 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492985 | 0.70 | CDC25B (0.39) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL31131321 | 0.70 | LMNA (0.45) | MEN1KMT2ACDC25BMAOAPTPRC | |
| Phthalimide SCHEMBL1388700 | 0.70 | APAF1 (0.44) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL27905984 | 0.70 | MEN1 (0.39) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL8026499 | 0.70 | MEN1 (0.39) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL3697487 | 0.70 | MEN1 (0.39) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL2359460 | 0.70 | IDO1 (0.44) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL879050 | 0.70 | CDC25B (0.39) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL19888 | 0.69 | MEN1 (0.50) | MEN1KMT2ACDC25BMAOAPTPRC | |
| SCHEMBL112133 | 0.69 | MEN1 (0.50) | MEN1KMT2ACDC25BMAOAPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102105466-B | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | CN | claimed |
| EP-3012250-A1 | ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2888251-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2015-07-01 | — | — | EP | disclosed |
| CN-102105466-B | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | CN | disclosed |
| WO-2014028968-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2014-02-27 | — | — | WO | disclosed |
| CN-102134214-B | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB | 2013-05-22 | — | — | CN | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| CN-102134214-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA SWEDEN AB | 2011-07-27 | — | — | CN | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| CN-101039907-B | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB | 2011-02-23 | — | — | CN | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-1934228-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1896461-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | Amgen Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| CN-101039907-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007027855-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | MEN1 2588/4885KMT2A 3975/4885CDC25B 3234/4885 |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | MEN1 1980/4885KMT2A 1625/4885CDC25B 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.